Revenue breakdown: Disposables (35.6%), Systems (29.1%), Distribution Agreement (26.7%).
6-K
IceCure Medical Ltd. announced a registered direct offering of 8,000,000 ordinary shares at $0.50 per share and a concurrent private placement of Series B and Series C warrants to purchase up to 16,000,000 ordinary shares, with expected gross proceeds of approximately $4.0 million. The company intends to use the net proceeds for working capital and other general corporate purposes.